About this item:

43 Views | 9 Downloads

Author Notes:

Correspondences, Nagadenahalli B. Siddappa, PhD, Dana-Farber Cancer Institute, JFB809, 44 Binney Street, Boston, MA 02115, USA. Tel.: 617 632 5628; fax: 617 632 3112; nb_siddappa@dfci.harvard.edu and Ruth M. Ruprecht, MD, PhD, Dana-Farber Cancer Institute, JFB809, 44 Binney Street, Boston, MA 02115, USA. Tel.: 617 632 3719; fax: 617 632 3112;ruth_ruprecht@dfci.harvard.edu.

We thank Elizabeth Samit for assistance in the preparation of this manuscript and Stephanie Ehnert, Chris Souder and Kalpana Patel for coordinating sample collections.

We thank Mahesh Bachu for help with phylogenetic analysis.

Subjects:

Research Funding:

This work was supported by National Institutes of Health grants P01 AI048240, R01 DE016013, and R37 AI034266 to R.M.R. Base grant RR-00165 provided support to the Yerkes National Primate Research Center.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Veterinary Sciences
  • clade C SHIV
  • neutralization sensitive
  • R5 SHIV
  • tier 1
  • vaccine development
  • NEIGHBOR-JOINING METHOD
  • TYPE-1 SUBTYPE-C
  • CORECEPTOR SWITCH
  • HIV-1 INFECTION
  • MACAQUES
  • ENV
  • ENVELOPE
  • ISOLATE
  • TRANSMISSION
  • CELLS

Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis

Show all authors Show less authors

Tools:

Journal Title:

Journal of Medical Primatology

Volume:

Volume 40, Number 2

Publisher:

, Pages 120-128

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Background While some recently transmitted HIV clade C (HIV-C) strains exhibited tier 1 neutralization phenotypes, most were tier 2 strains (J Virol 2010; 84:1439). Because induction of neutralizing antibodies (nAbs) through vaccination against tier 2 viruses has proven difficult, we have generated a tier 1, clade C simian-human immunodeficiency virus (SHIV-C) to permit efficacy testing of candidate AIDS vaccines against tier 1 viruses. Methods SHIV-1157ipEL was created by swapping env of a late-stage virus with that of a tier 1, early form. Results After adaptation to rhesus macaques (RM), passaged SHIV-1157ipEL-p replicated vigorously in vitro and in vivo while maintaining R5 tropism. The virus was reproducibly transmissible intrarectally. Phylogenetically, SHIV-1157ipEL-p Env clustered with HIV-C sequences. All RM chronically infected with SHIV-1157ipEL-p developed high nAb titers against autologous as well as heterologous tier 1 strains. Conclusions SHIV-1157ipEL-p was reproducibly transmitted in RM, induced cross-clade nAbs, and represents a tool to evaluate anti-HIV-C nAb responses in primates.

Copyright information:

© 2010 John Wiley & Sons A/S.

Export to EndNote